Oramed Pharm (ORMP) AI Stock Analysis

Compare

522 Followers

ORMP Dividends

Top Page

Oramed Pharm

(NASDAQ:ORMP)

47Neutral

Oramed Pharm's overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.

Positive Factors

Investment

The joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.

Joint Venture

Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.

Negative Factors

Clinical Efficacy

The candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.

Oramed Pharm (ORMP) vs. S&P 500 (SPY)

Market Cap

$95.18M

Dividend YieldN/A

Average Volume (3M)65.81K

Price to Earnings (P/E)21.1

Beta (1Y)0.95

Revenue Growth-100.00%

EPS GrowthN/A

CountryUS

Employees13

SectorHealthcare

Sector Strength69

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.48

Shares Outstanding40,850,456

10 Day Avg. Volume51,817

30 Day Avg. Volume65,815

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)70.09

Price to Cash Flow (P/CF)-3.30

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Oramed Pharm Business Overview & Revenue Model

Company DescriptionOramed Pharmaceuticals Inc. (ORMP) is a clinical-stage pharmaceutical company focused on the development of innovative oral drug delivery solutions. The company operates primarily in the biotechnology sector, aiming to transform injectable treatments into oral alternatives. Its flagship product is an oral insulin capsule for the treatment of diabetes, which is designed to improve the quality of life for millions of diabetic patients worldwide.

How the Company Makes MoneyOramed Pharmaceuticals generates revenue primarily through the development and potential commercialization of its oral drug delivery technology. The company's revenue model is heavily reliant on successful clinical trials and the subsequent approval and licensing of its products. Oramed partners with pharmaceutical companies to co-develop and license its technologies, receiving milestone payments and royalties from these collaborations. Additionally, the company may engage in research and development service agreements, contributing to its revenue streams. However, as a clinical-stage company, its current earnings are mostly derived from partnerships and investments aimed at advancing its clinical programs.

Oramed Pharm Financial Statement Overview

Summary

Oramed Pharm's financial performance is mixed. The income statement is weak due to zero revenue and negative EBIT, while the balance sheet is strong with a high equity ratio. Cash flow is negative, indicating liquidity issues.

Income Statement

Negative

Oramed Pharm's income statement reflects significant challenges, primarily due to zero revenue in the TTM, a negative EBIT, and fluctuating net income figures. The lack of revenue growth and negative margins highlight ongoing operational inefficiencies.

Balance Sheet

Neutral

The balance sheet shows a strong equity position with a high equity ratio, indicative of financial stability. However, the debt-to-equity ratio is low, providing some leverage risk, but overall liabilities remain manageable relative to equity.

Cash Flow

Negative

Cash flow analysis reveals negative operating and free cash flows, indicating potential liquidity issues. The operating cash flow to net income ratio is unfavorable, suggesting challenges in converting income into cash flow.

TTM	Dec 2023	Dec 2022	Sep 2021	Sep 2020	Sep 2019
Breakdown
Income Statement		Total Revenue
0.00	1.34M	2.70M	2.70M	2.71M	2.70M
	Gross Profit
0.00	1.34M	2.70M	2.70M	2.62M	2.61M
	EBIT
-13.06M	-15.77M	-40.60M	-24.22M	-11.76M	-14.63M
	EBITDA
24.86M	-15.57M	-36.98M	-25.04M	-11.31M	-14.17M
	Net Income Common Stockholders
4.46M	5.53M	-37.76M	-22.24M	-11.51M	-14.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.34M	162.05M	155.72M	94.14M	39.90M	32.28M
	Total Assets
5.96M	220.55M	161.64M	128.00M	44.63M	34.66M
	Total Debt
0.00	51.62M	894.00K	533.00K	75.00K	0.00
	Net Debt
-2.04M	42.57M	-39.57M	-76.71M	-19.22M	-3.33M
	Total Liabilities
709.29K	57.66M	10.49M	11.48M	11.75M	15.27M
	Stockholders Equity
5.25M	163.82M	151.81M	115.77M	32.88M	19.39M
Cash Flow		Free Cash Flow
-7.93M	-10.55M	-28.41M	-21.56M	-12.52M	-12.96M
	Operating Cash Flow
-7.92M	-10.29M	-27.92M	-21.18M	-12.44M	-12.94M
	Investing Cash Flow
120.39M	-73.04M	30.21M	-23.76M	4.63M	11.26M
	Financing Cash Flow
-75.84M	51.98M	10.78M	102.89M	23.79M	0.00

Oramed Pharm Technical Analysis

Technical Analysis Sentiment

Positive

Last Price2.33

Price Trends

50DMA

2.26

Positive

100DMA

2.31

Positive

200DMA

2.35

Negative

Market Momentum

MACD

<0.01

Negative

RSI

57.02

Neutral

STOCH

94.31

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Positive. The current price of 2.33 is above the 20-day moving average (MA) of 2.19, above the 50-day MA of 2.26, and below the 200-day MA of 2.35, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.02 is Neutral, neither overbought nor oversold. The STOCH value of 94.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORMP.

Oramed Pharm Risk Analysis

Oramed Pharm disclosed 45 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Oramed Pharm Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	66 Neutral	$2.08B	48.01	-0.53%	―	27.28%	-101.63%
MNKD	56 Neutral	$1.44B	51.80	-35.00%	―	43.50%	―
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
ORMP	47 Neutral	$95.18M	21.10	-12.29%	―	-100.00%	―
AMRN	47 Neutral	$216.00M	―	-15.79%	―	-25.86%	-37.19%
VSTM	44 Neutral	$386.17M	―	-526.33%	―	―	14.39%
RDHL	38 Underperform	$3.07M	―	1155.92%	―	―	―

* Healthcare Sector Average

Performance Comparison

ORMP

Oramed Pharm

2.33

-0.11

-4.51%

AMRN

Amarin

10.43

-7.11

-40.54%

LGND

Ligand Pharma

108.07

37.61

53.38%

MNKD

MannKind

4.74

0.48

11.27%

VSTM

Verastem

7.50

-2.13

-22.12%

RDHL

RedHill Biopharma

2.41

-8.41

-77.73%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.